ARTICLE | Deals
Pfizer promises expanded global reach for sickle cell drug in $5.4B GBT takeout
Pharma gains rights to Oxbryta along with a sickle cell pipeline that could deliver $3B in peak sales
August 8, 2022 8:40 PM UTC
With the $5.4 billion buyout of Global Blood Therapeutics, Pfizer believes it can expand the reach of the biotech’s sickle cell franchise with the aim of addressing a health equity issue in the developing world.
The deal will give Pfizer Inc. (NYSE:PFE) one approved drug from Global Blood Therapeutics Inc. (NASDAQ:GBT), Oxbryta voxelotor, plus a pipeline of other sickle cell disease (SCD) therapies. The companies believe the franchise could deliver peak annual sales of more than $3 billion...